Investigator-Initiated Studies (IIS) - Sarepta Therapeutics

About this program

Sarepta Therapeutics funds investigator-initiated studies (IIS) to support independent clinical or non-clinical research that advances precision genetic medicine for rare neuromuscular diseases, providing financial and/or material support aligned with its therapeutic focus. Eligible applicants include individual investigators, institutions, or research groups proposing studies within Sarepta’s core rare disease areas. Proposals are accepted on a rolling basis, reviewed monthly with feedback within 90 days, and require submission of a concept or full proposal through Sarepta Medical Affairs or via IIS@sarepta.com; consult the program FAQ for application requirements, evaluation criteria, and sponsor responsibilities.